Epitalon: FDA status, legal access, dosage and side effects
What the peptide is, what changed in October 2026, and what the research does and does not show.
Epitalon (also spelled Epithalon) is a synthetic four-amino-acid peptide, Ala-Glu-Asp-Gly, modeled on a pineal-gland extract and studied mostly in Russian lab, animal and small human studies. It is not FDA-approved. Since October 30, 2026, an interim HHS policy lets 503A pharmacies compound it by prescription. REMEVi does not currently offer Epitalon.
Epitalon is not FDA-approved. Since HHS’s October 2026 interim policy, a state-licensed 503A pharmacy may compound it on a patient-specific prescription under listed conditions.
REMEVi does not currently offer Epitalon.
What changed in 2026
On October 30, 2026, the Federal Register published notice of HHS’s interim enforcement-discretion policy for 503A compounding (Federal Register, October 30, 2026). HHS said it does not intend to take enforcement action against a state-licensed pharmacy or federal facility that compounds a drug from one of six listed peptides, Epitalon among them, while the 503A bulks list is developed through rulemaking.
For Epitalon, the policy’s appendix lists epitalon acetate for injection, given in intermittent courses. Secondary reports note that the policy does not define “intermittent courses.” Every condition below must be met:
- A patient-specific prescription from a licensed prescriber.
- Compounding by a state-licensed 503A pharmacy (503B outsourcing facilities are not covered).
- The peptide and route match the appendix: for Epitalon, injection in intermittent courses.
- Bulk substance from an FDA-registered facility with a valid certificate of analysis (CoA); the original manufacturer is FDA-registered and CGMP-compliant.
- A single active ingredient per product: no combination products.
- No device other than an FDA 510(k)-cleared syringe packaged with or containing the drug.
- The label reads “This is a compounded drug product. Not for resale.”
- Serious adverse events are reported to FDA MedWatch.
The policy is interim, non-binding and revocable: HHS may revisit it if a safety signal or product quality issue arises. It is not FDA approval and does not add Epitalon to the 503A bulks list. Public comments were open for two weeks after October 30 (docket HHS-OASH-2026-0496).
Read the Federal Register notice · The 2026 HHS peptide policy, explained
How a legal Epitalon prescription works
- A licensed provider evaluates you and decides whether Epitalon is appropriate. Many will not prescribe it, given how little human data exists.
- If they do, they write a prescription for you by name: a patient-specific prescription, not an office-stock order.
- A state-licensed 503A compounding pharmacy prepares it by injection from a registered, CoA-documented bulk source, as a single-ingredient product.
- The product arrives labelled “This is a compounded drug product. Not for resale.” Any serious adverse event is reported to FDA MedWatch.
REMEVi does not currently offer Epitalon, so REMEVi does not take part in any step of this path for it.
Research-grade vials vs compounded prescriptions
Vials sold online “for research use” are not compounded prescriptions and sit outside the HHS policy. They are not prepared for a named patient, not dispensed by a licensed pharmacy, and carry no requirement for a registered bulk source, a certificate of analysis or MedWatch reporting.
On August 24, 2026, FDA sent warning letters to five online peptide vendors; per Holland & Knight, “research use” labels did not outweigh evidence that the products were meant for people. A 2015 laboratory analysis also identified Epitalon in two illegal pharmaceutical preparations.
What research exists on Epitalon
Most Epitalon research is laboratory and animal work, much of it from one group of Russian investigators. Human data are small and old, and there are no meaningful human outcome data. A 2026 review in the International Journal of Molecular Sciences concluded that Epitalon is biologically active but not clinically established, with no adequately powered randomized trial.
- Cell studies: a 2025 study reported longer telomeres in human cell lines, through telomerase in normal cells and through a different pathway (ALT) in breast cancer cell lines.
- Animal studies: rodent work has looked at pineal hormones, the retina and tumor development in mice; animal findings do not tell you what happens in people.
- Human studies: small Russian studies measured biomarkers, such as melatonin output in older adults, and one older controlled study looked at retinitis pigmentosa. Randomization and blinding are unclear in these reports.
- Epithalamin is not Epitalon: frequently cited long-term follow-up studies used Epithalamin, a pineal extract, rather than the synthetic peptide.
At FDA’s July 2026 advisory committee meeting, FDA staff recommended against adding Epitalon to the 503A bulks list, citing limited human safety data, immunogenicity questions and insufficient evidence of effectiveness; the committee’s narrow favorable vote was advisory.
Epitalon side effects: summary
The small human studies reported few adverse effects, but they were not designed to find them, and no dedicated human safety study exists. Because Epitalon has been studied for telomerase activity, FDA’s 2026 review flagged a possible cancer-related concern that current data cannot settle. Injection-site reactions are possible with any injection.
Epitalon dosage: summary
The one human injection study of synthetic Epitalon we could trace used a small daily amount for a 10-day course. Online charts list far larger amounts. Published protocols vary; a licensed provider sets your dose; never self-dose.
Epitalon dosage: published protocols · Epitalon courses: published course lengths
Epitalon cost: summary
Published prices for prescribed Epitalon vary widely by channel, and most were posted before the October 2026 policy. Research-grade vials list for less because they skip the prescription, pharmacy and quality steps. REMEVi does not currently price Epitalon.
Is Epitalon legal in the US?
Epitalon is not FDA-approved. Since October 30, 2026, HHS’s interim policy says it will not take enforcement action when a state-licensed 503A pharmacy compounds Epitalon for injection on a patient-specific prescription and meets every listed condition. The policy is non-binding and revocable, and it does not cover vials labelled for research use.
Do you need a prescription for Epitalon?
Yes, for a compounded product covered by the HHS policy. The policy requires a patient-specific prescription from a licensed prescriber, filled by a state-licensed 503A pharmacy. Products sold without a prescription as “research chemicals” are outside the policy and are not compounded prescriptions, whatever their label or website says.
What is Epitalon used for?
Epitalon is not FDA-approved for any use. It has been studied in cell and animal models of telomere biology and pineal hormone function, and in small Russian human studies measuring melatonin output and retinal findings. A 2026 review found no adequately powered randomized trial showing it treats any condition. Human outcome data are essentially absent.
How long is an Epitalon cycle?
The HHS policy says Epitalon is given in “intermittent courses” but does not define them. Published human studies of the synthetic peptide used courses of 10 days by injection and 20 days by a non-injected route. A licensed provider decides whether a course is appropriate, how long it runs and whether it repeats.
More questions
Does REMEVi offer Epitalon?
No. REMEVi does not currently offer Epitalon. REMEVi prescribes NAD+, sermorelin and GLP-1 treatment through licensed pharmacies; those pages are linked below.
Is Epitalon the same as Epithalamin?
No. Epithalamin is a pineal-gland extract. Epitalon is a synthetic four-amino-acid peptide modeled on it. Several widely cited long-term human studies used Epithalamin, so their results do not describe Epitalon.
Sources
- HHS — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, 91 FR 68526 (Federal Register, October 30, 2026) (read November 2, 2026)
- Foley & Lardner, National Law Review 2026 — Peptides: HHS announces limited enforcement discretion for compounding six peptides (read November 2, 2026)
- Nutritional Outlook 2026 — HHS peptide compounding policy: supplement industry implications (read November 2, 2026)
- AJMC 2026 — 5 things to know about HHS’s interim peptide compounding policy (read November 2, 2026)
- Holland & Knight 2026 — Peptides at a crossroads: what wellness providers need to know (read November 2, 2026)
- Jain et al., Int J Mol Sci 2026 — Epitalon and Epithalamin: a narrative review of mechanistic, preclinical, and clinical evidence (read November 2, 2026)
- Araj et al., Int J Mol Sci 2025 — Overview of Epitalon: highly bioactive pineal tetrapeptide with promising properties (read November 2, 2026)
- Al-Dulaimi et al., Biogerontology 2025 — Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity (read November 2, 2026)
- Khavinson et al., Neuro Endocrinol Lett 2002 — Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa (read November 2, 2026)
- Khavinson & Morozov, Neuro Endocrinol Lett 2003 — Peptides of pineal gland and thymus prolong human life (read November 2, 2026)
- Kossoy et al., In Vivo 2006 — Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice (read November 2, 2026)
- Vanhee et al., Drug Test Anal 2015 — Identification of the small research tetra peptide Epitalon … in two illegal pharmaceutical preparations (read November 2, 2026)
Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·